Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00804076 · ClinicalTrials.gov registry record · Phase 1

Gene Transfer for Cancer Pain

A Phase 1 study of Cancer Pain, sponsored by Diamyd.

Completed
Registry status
Phase 1
Development phase
10
Enrollment target
5
Study locations

NCT00804076 is a Phase 1 study of Cancer Pain that has completed, run by Diamyd. The registered enrollment target is 10 participants, below the 162-participant average among 15 other Cancer Pain trials with a reported enrollment target (94% lower). The trial reports 5 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00804076, a Phase 1 study of Cancer Pain, has completed, sponsored by Diamyd.

COMPLETED
Registry status
Phase 1
Development phase
10 participants
Enrollment target
5
Study locations

Study Summary

The primary purpose of this study is to examine the safety of NP2 (a nonreplicating HSV-based vector expressing enkephalin) in patients with cancer pain. The secondary purpose is to evaluate efficacy.

Conditions Studied

Interventions

  • BIOLOGICAL NP2

Study Locations (5)

Florida

  • Advanced Pharma CR - Miami

Louisiana

  • Louisiana Research Associates - New Orleans

Michigan

  • University of Michigan Medical Center - Ann Arbor

North Carolina

  • Center for Clinical Research - Winston-Salem

Oregon

  • Pain Research of Oregon, LLC - Eugene

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2008-02
Est. Completion 2013-07
Phase Phase 1

Sponsor

Diamyd

2 total trials

What the Registry Record Tells You About NCT00804076

The ClinicalTrials.gov registry entry for NCT00804076 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 162-participant average among 15 other Cancer Pain trials with a reported enrollment target (94% lower). The listed sponsor is Diamyd, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Cancer Pain appearing as the primary indexed condition, and to 1 intervention - of which NP2 is the first listed.

NCT00804076 reports 5 study locations spanning 5 distinct geographic areas - top geographies include Florida, Louisiana, Michigan.

Frequently Asked Questions

What is clinical trial NCT00804076 about?

NCT00804076 is a clinical study titled "Gene Transfer for Cancer Pain". The primary purpose of this study is to examine the safety of NP2 (a nonreplicating HSV-based vector expressing enkephalin) in patients with cancer pain. The secondary purpose is to evaluate efficacy.

What is the current status of trial NCT00804076?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2008-02. Estimated completion is 2013-07.

What conditions does trial NCT00804076 study?

This clinical trial studies the following conditions: Cancer Pain.

What interventions are being tested in trial NCT00804076?

The interventions under investigation include: NP2 (BIOLOGICAL).

Who is sponsoring clinical trial NCT00804076?

This trial is sponsored by Diamyd, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00804076 being conducted?

This trial has 5 study locations across Florida, Louisiana, Michigan, North Carolina, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cancer Pain

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.